Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUN 8 ... Patent Actions, Patents Actions, Pharmaceuticals, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Biotech Business Week editors from staff ...
2009 JUN 29 ... Regulatory Actions, Therapies, Therapy, Treatment, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Pain & Central Nervous System Week editors ...
2009 JUL 13 ... (INS) product, AllerNaze(TM) (triamcinolone acetonide, USP) Nasal Spray, 50mcg from CollegiumPharmaceutical, Inc. The United States will be the first market in which ...
2009 NOV 9 ... from the Garden of Medicinal Plants of the Faculty of Pharmacy, Jagiellonian University, Collegium Medicum in Krakw were investigated. Arbuscular mycorrhiza (AM) was found in 30 species; ... "The use of AMF and DSE during the process of medicinal plant cultivation for pharmaceutical purposes is discussed." Zubek and colleagues published their study in ...
2008 APR 21 ... studies and the development of a proprietary product formulation with its partner CollegiumPharmaceutical in preparation for US IND submission.
Keywords: Adult ...
2008 JUL 28 ... Hydrochloride, Patents Actions, Pharmaceuticals, Regulatory Actions, Therapy, Treatment, Collegium Pharmaceutical Inc.
This article was prepared by Biotech Business Week editors from staff ...
2008 FEB 25 ... Patents Actions, Pharmaceuticals, Therapy, Treatment, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Biotech Business Week editors from staff ...
2007 JUL 2 ... Patents, Pharmaceuticals, Therapy, Treatment, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Biotech Business Week editors from staff ...
2007 AUG 27 ... Therapy, Treatment, Triamcinolone Acetonide, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Biotech Business Week editors from staff ...
2007 DEC 31 ... Regulatory Actions, Therapy, Treatment, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Biotech Business Week editors from staff ...
2008 NOV 17 ... Mr. Heffernan is a co-founder and has served as President and Chief Executive Officer of CollegiumPharmaceutical, Inc. since 2002. Collegium is a specialty pharmaceutical company that ...
2007 APR 30 ... 2007;59(4):495-501).
For additional information, contact E. Wyska, Collegium Medicum, Dept. of Pharmacokinetics and Physical Pharmacy, Jagiellonian University, 9 ... Publisher contact information for the Journal of Pharmacy and Pharmacology is: Royal Pharmaceutical Society Great Britain, 1 Lambeth High St., London SE1 7JN, England.
...
2007 AUG 6 ... a multinational, multicenter phase III study presented at the Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).
Because paliperidone ... at Johnson & Johnson.
Report 1: Researchers at Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced that they have discovered a biological ... charge of $87 million associated with the acquisition of Vascular Control Systems Inc. Prior-year second quarter net earnings included after-tax in-process research and ...
2007 MAY 14 ... a multinational, multicenter phase III study presented at the Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).
Because paliperidone ... to use the OROS extended-release technology, according to Johnson & Johnson Pharmaceutical Research & Development, LLC, sponsor of the study. This technology provides a consistent ... most recent news developments at Johnson & Johnson.
Report 1: Therakos, Inc., a Johnson & Johnson company, announced today that the Centers for Medicare & Medicaid ...
2007 MAY 29 ... a multinational, multicenter phase III study presented at the Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).
Because paliperidone ... to use the OROS extended-release technology, according to Johnson & Johnson Pharmaceutical Research & Development, LLC, sponsor of the study. This technology provides a consistent ... Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals, Inc., (VRTX) to develop and commercialize Vertex's investigational hepatitis C virus (HCV) ...
2007 APR 3 ... a multinational, multicenter phase III study presented at the Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).
Because paliperidone ... to use the OROS extended-release technology, according to Johnson & Johnson Pharmaceutical Research & Development, LLC, sponsor of the study. This technology provides a consistent ... Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals, Inc., (VRTX) to develop and commercialize Vertex's investigational hepatitis C virus (HCV) ...
2007 AUG 29 ... Research, FDA, Immunology, Patents, Pharmaceuticals, U.S. Food and Drug Administration, Collegium Pharmaceutical Inc.
This article was prepared by Medical Patent Law Week editors from staff ...
2007 JUL 10 ... Molecular and Clinical Medicine, Linkoping University, Sweden.
Study 2: CollegiumPharmaceutical, Inc., a specialty pharmaceutical company, announced the results of its ...
